tapebrief
NDSN · Q2 2026
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

NDSN · Q2 2025 Earnings

Nordson Corporation

Reported May 28, 2025

30-second summary

30-second take: Nordson delivered $683M in Q2 revenue, +5% YoY, with the mix shifting decisively — Advanced Technology Solutions grew 18% on semiconductor/HPC strength and Medical and Fluid Solutions grew 20% (Atrion-led), while Industrial Precision Solutions fell 7.6% on weak industrial systems demand. Non-GAAP EPS of $2.42 and 32% EBITDA margin held up despite the IPS drag, and management restructured IPS for >$15M of 2026 annual savings. The Q3 guide ($710–750M revenue, $2.55–2.75 EPS) implies sequential improvement, but management explicitly stopped short of reiterating the full-year range pending tariff policy outcomes — a quiet hedge worth noting.

Headline numbers

EPS

Q2 FY2025

$2.42

Revenue

Q2 FY2025

$0.68B

+5.0% YoY

Gross margin

Q2 FY2025

54.7%

Operating margin

Q2 FY2025

24.7%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$0.68B+5.0%
EPS$2.42—
Gross margin54.7%—
Operating margin24.7%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Industrial Precision Solutions$0.319B-7.6%
Medical and Fluid Solutions$0.203B+20.0%
Advanced Technology Solutions$0.161B+18.0%
Organic Sales Growth (IPS)-6.9%—
Organic Sales Growth (MFS)-10.0%—
Organic Sales Growth (ATS)+18.1%—

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Americas$0.292B-0.7%
Europe$0.172B-5.3%
Asia Pacific$0.218B+25.2%
EBITDA$217 million—
EBITDA Margin32%—
Backlog Growth+5%—
Share Repurchase$85 million—
Acquisition Impact on Sales8%—

Management tone

Five distinct shifts emerge from this quarter's commentary, mostly favorable but framed with unusual caution about the back half.

ATS shifted from cyclical drag to confirmed growth phase. For several prior quarters, ATS had been a wait-and-see story tied to semiconductor capex timing. Management's "we are now seeing it in our businesses and we're seeing it in our results" anchors the transition from forward-looking optimism to booked performance. The disclosure that HPC/semi is now ~50% of ATS versus ~30% historically reframes the segment from volatile cyclical to structurally exposed to AI infrastructure buildout — a materially different investment narrative.

Medical destocking is finally rolling off. The framing moved from "destocking is a persistent headwind" to "destocking continue to reduce in severity," with the fluid components business — down for several quarters — "now delivering nice growth." Combined with order entry improvement, this suggests the MFS organic decline of -10% is the trough rather than a new normal. Worth verifying against next quarter's organic print.

IPS shifted from structurally challenged to actively restructured. Management didn't pretend IPS was fine; instead they're cutting cost with >$15M of 2026 annual savings and pointing to sequential improvement. The honesty here is useful — it implies the YoY weakness persists for "another couple of quarters" on the automotive side, but the cost base will be reset before demand returns.

Tariffs reframed from material risk to non-event. The "85–90% in-region, for-region" disclosure quantifies what had previously been qualitative resilience claims. Management said tariff impact was "not material" to Q2 results. That said, the hedge that "things can change and we're continuing to monitor" pairs with the conspicuous non-reiteration of full-year guidance — implying the residual risk is real but unquantifiable.

Portfolio rationalization is now an annual process, not a one-time event. Post-plastics-divestiture, management explicitly stated "portfolio analysis happens every year." The pending medical divestiture (4% of medical YTD sales, ~100bps margin accretion) is positioned as a margin-improvement transaction, not a forced exit. This sets up a recurring optimization cadence investors should expect.

Recurring themes management leaned on this quarter:

Semiconductor/high-performance computing demand acceleration driving ATS growthMedical segment margin accretion through portfolio optimization and Atrion integration outperformancePrecision agriculture (ARAG) return to double-digit organic growth in Europe and South AmericaIndustrial systems stabilization through cost restructuring and sequential improvementTariff mitigation via in-region manufacturing footprint and supply chain agilityNBS Next operational framework driving margin expansion and efficiency

Risks management surfaced:

Automotive end-market headwinds expected to persist for 'another couple of quarters'Tariff policy uncertainty with July/August deadlines creating potential for end-market demand pullbackATS segment inherent lumpiness due to customer capital expansion/contraction timingQ4 visibility limited pending policy developments and potential customer investment deferralsSemiconductor customer footprint diversification creating execution complexity

What to watch into next quarter

Whether IPS organic growth inflects positive in Q3 as management's "continued sequential improvement" language implies, or whether automotive weakness extends the down cycle

MFS organic growth excluding Atrion — needs to move from -10% toward zero to validate the "destocking severity reducing" narrative

ATS book-to-bill and any commentary on whether the +18% organic pace is sustainable into Q4, given the inherent lumpiness management acknowledged

Whether management reiterates a specific full-year revenue/EPS range when Q3 prints, or continues to dodge — the non-reiteration this quarter is a soft signal

Medical divestiture close timing (expected Q4 FY2025) and the actual ~100bps margin accretion claim post-close

IPS restructuring completion and whether the >$15M annual run-rate benefit shows up in Q4 segment margins as guided

Sources

  1. Nordson Corporation Q2 FY2025 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233125000053/ndsn-q220258kxex991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.